# 2025年12月6日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 一例致死性H5N1禽流感病例中的I型干扰素中和自身抗体

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41348320](https://pubmed.ncbi.nlm.nih.gov/41348320)
**期刊：** The Journal of experimental medicine
**PMID：** 41348320
**DOI：** 10.1084/jem.20251962

### 第一部分 原文与翻译

**英文原标题：** Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza.

**英文摘要原文：**
Avian influenza A virus (IAV) H5N1 is an emerging threat of human pandemic. We describe a 71-year-old man who died of H5N1 pneumonia in Louisiana and whose blood contained autoantibodies neutralizing type I IFNs (AAN-I-IFNs), including the 12 IFN-α subtypes (1-10 ng/ml) and IFN-ω (100 pg/ml). Causality between these AAN-I-IFN and lethal outcome of avian influenza in this patient is based on (1) our previous report that AA-I-IFN underlie about 5% of cases of critical pneumonia triggered by seasonal influenza viruses in three cohorts, (2) the rarity of this combination of AAN-I-FNs in individuals over 70 years old (<1%), and (3) the rarity of lethal avian influenza among infected individuals (<1%). AAN-I-IFNs underlie a growing number of severe viral diseases, from arboviral encephalitis to viral pneumonia, particularly in the elderly. This case suggests they can also underlie life-threatening avian H5N1 influenza. The presence of AAN-I-IFN may facilitate infection, replication, and adaptation of zoonotic IAVs to humans and, therefore, human-to-human transmission.

**中文摘要译文：**
禽流感A病毒（IAV）H5N1是人类大流行的新兴威胁。我们描述了一名在路易斯安那州死于H5N1肺炎的71岁男性患者，其血液中含有中和I型干扰素的自身抗体（AAN-I-IFNs），包括12种IFN-α亚型（1-10 ng/ml）和IFN-ω（100 pg/ml）。这些AAN-I-IFNs与该患者禽流感致死结局之间的因果关系基于以下三点：(1)我们之前的报告显示，在三个队列中，AA-I-IFN是约5%由季节性流感病毒引发的重症肺炎病例的基础；(2)这种AAN-I-FNs组合在70岁以上个体中极为罕见（<1%）；(3)禽流感感染个体中的致死病例极为罕见（<1%）。AAN-I-IFNs是越来越多严重病毒性疾病的基础，从虫媒病毒性脑炎到病毒性肺炎，尤其在老年人中。本病例表明它们也可能构成危及生命的禽H5N1流感的基础。AAN-I-IFN的存在可能促进人畜共患IAVs的感染、复制和适应人类，从而促进人际传播。

### 第二部分 AI 大师评价

本研究通过一例致死性H5N1禽流感病例报告，首次揭示了I型干扰素中和自身抗体（AAN-I-IFNs）在禽流感致命结局中的潜在作用。研究采用病例分析与流行病学数据相结合的方法，基于三个关键证据链建立了AAN-I-IFNs与致死结局的因果关系。其创新性在于将已知的免疫缺陷机制扩展到禽流感领域，为理解高危人群的易感性提供了新的病理生理学视角。该发现具有重要的临床价值，提示检测AAN-I-IFNs可能有助于识别流感高危患者群体，并为开发针对性预防和治疗策略提供依据。然而，作为单病例报告，其结论需要在更大样本的前瞻性研究中验证，且对AAN-I-IFNs促进病毒适应人类的具体机制仍需进一步探索。

---

## 2. 暴发性单纯疱疹病毒性肝炎患者中中和I型干扰素的自身抗体

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41348319](https://pubmed.ncbi.nlm.nih.gov/41348319)
**期刊：** The Journal of experimental medicine
**PMID：** 41348319
**DOI：** 10.1084/jem.20251760

### 第一部分 原文与翻译

**英文原标题：** Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.

**英文摘要原文：**
Fulminant viral hepatitis (FVH) is a devastating condition caused by hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV), and HSV-1/2. We studied 149 FVH patients (73 males and 76 females, aged 1-76) for blood autoantibodies (auto-Abs) neutralizing type I interferons (IFNs; IFN-α2, -β, -ω). Six of 16 (37.5%) HSV-triggered FVH patients carried such auto-Abs on admission, including three with a previously known autoimmune disease. These patients contrasted with 133 HAV- (n = 46) or HBV-triggered (n = 87) patients, none of whom had such detectable auto-Abs. Odds ratios for HSV-triggered FVH in individuals with auto-Abs ranged from 35.3 (95% CI: 13.0-96.2; P < 10-7) for those neutralizing only 100 pg/ml IFN-α/ω to 1,895 (CI: 448.5-8,002; P < 10-12) for those neutralizing both IFN-α and IFN-ω at 10 ng/ml. Over one third of HSV-triggered FVH cases in this international cohort were due to preexisting auto-Abs. This finding highlights auto-Abs against type I IFNs as a major determinant of HSV-FVH and paves the way for targeted preventive or therapeutic interventions.

**中文摘要译文：**
暴发性病毒性肝炎（FVH）是由嗜肝病毒如甲型肝炎病毒（HAV）、乙型肝炎病毒（HBV）和HSV-1/2引起的一种破坏性疾病。我们研究了149例FVH患者（73名男性和76名女性，年龄1-76岁）血液中中和I型干扰素（IFN-α2、-β、-ω）的自身抗体。在16例HSV引发的FVH患者中，有6例（37.5%）在入院时携带此类自身抗体，其中包括3例先前已知患有自身免疫性疾病的患者。这些患者与133例HAV引发（n=46）或HBV引发（n=87）的患者形成对比，后者均未检测到此类自身抗体。携带自身抗体的个体发生HSV引发FVH的比值比范围从仅中和100 pg/ml IFN-α/ω者的35.3（95% CI：13.0-96.2；P < 10⁻⁷）到同时中和10 ng/ml IFN-α和IFN-ω者的1,895（CI：448.5-8,002；P < 10⁻¹²）。在这个国际队列中，超过三分之一的HSV引发FVH病例是由于预先存在的自身抗体所致。这一发现强调了抗I型干扰素的自身抗体是HSV-FVH的主要决定因素，并为靶向预防或治疗干预铺平了道路。

### 第二部分 AI 大师评价

本研究旨在探索暴发性单纯疱疹病毒性肝炎（HSV-FVH）患者中I型干扰素中和性自身抗体的存在及其临床意义。研究团队采用病例对照设计，对149例不同病因的暴发性病毒性肝炎患者进行了系统性检测。关键发现揭示了超过三分之一的HSV-FVH患者携带此类自身抗体，且与HAV/HBV引发的病例形成鲜明对比，统计学关联极其显著（OR值高达1,895）。这一发现具有重要创新性，首次明确了I型干扰素自身抗体在HSV-FVH发病机制中的核心作用，为理解特定人群对HSV严重感染的易感性提供了全新视角。研究不仅具有重要临床价值——为高危人群筛查和靶向干预提供了理论基础，也开辟了自身免疫与病毒感染交叉领域的新研究方向，尽管研究样本量有限且为观察性设计，但其发现为未来预防性和治疗性策略的开发奠定了坚实基础。

---

## 3. EL219（一种新一代多烯类抗真菌药）在免疫抑制小鼠中对药物敏感和耐药菌株感染的疗效评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41347521](https://pubmed.ncbi.nlm.nih.gov/41347521)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41347521
**DOI：** 10.1128/aac.01400-25

### 第一部分 原文与翻译

**英文原标题：** Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant isolates.

**英文摘要原文：**
Invasive pulmonary aspergillosis (IPA), mainly caused by remains a life-threatening fungal infection, with rising reports of infections caused by resistant species such as and . EL219 (formerly known as SF001) is a novel, next-generation polyene with enhanced ergosterol selectivity and reduced nephrotoxicity. We evaluated the efficacy of EL219 compared to liposomal amphotericin B (LAMB) using the Clinical Laboratory and Standards Institute M38 methodology and in immunosuppressed murine models of IPA caused by , , and . Immunosuppressed ICR mice were infected via inhalation () or via intratracheal instillation ( and ), then treated intravenously once daily with placebo, EL219 (0.3, 1.5, 7.5, and 30 mg/kg), or LAMB (5 mg/kg) starting 16 h post-infection. Treatment lasted 4 days ( and ) or 7 days (). Survival through Day 21 and lung fungal burden at Day 4 were assessed. EL219 showed enhanced activity against and compared to LAMB. EL219 significantly improved survival in a dose-dependent manner, with 30 mg/kg outperforming LAMB. EL219 also resulted in >5-log fungal burden reductions in -infected lungs. EL219 demonstrated broad-spectrum efficacy, improved survival, and reduced lung fungal burden, supporting its potential as a novel therapy for IPA.

**中文摘要译文：**
侵袭性肺曲霉病（IPA）主要由曲霉菌引起，仍然是一种危及生命的真菌感染，由耐药菌株如烟曲霉和土曲霉引起的感染报告日益增多。EL219（曾用名SF001）是一种新型的新一代多烯类药物，具有增强的麦角固醇选择性和降低的肾毒性。我们使用临床实验室和标准协会M38方法学，并在由烟曲霉、土曲霉和黑曲霉引起的免疫抑制小鼠IPA模型中，评估了EL219与脂质体两性霉素B（LAMB）的疗效比较。免疫抑制的ICR小鼠通过吸入（烟曲霉）或气管内滴注（土曲霉和黑曲霉）感染，然后在感染后16小时开始每天静脉注射一次安慰剂、EL219（0.3、1.5、7.5和30 mg/kg）或LAMB（5 mg/kg）。治疗持续4天（土曲霉和黑曲霉）或7天（烟曲霉）。评估了第21天的存活率和第4天的肺部真菌负荷。与LAMB相比，EL219对烟曲霉和土曲霉显示出增强的活性。EL219以剂量依赖性方式显著提高了存活率，30 mg/kg剂量优于LAMB。EL219还在烟曲霉感染的肺部导致>5个对数的真菌负荷减少。EL219显示出广谱疗效、改善存活率和减少肺部真菌负荷，支持其作为IPA新型疗法的潜力。

### 第二部分 AI 大师评价

本研究旨在评估新一代多烯类抗真菌药EL219在免疫抑制小鼠模型中对药物敏感和耐药曲霉菌株的疗效。研究采用临床实验室标准协会M38方法学，建立了由烟曲霉、土曲霉和黑曲霉引起的侵袭性肺曲霉病小鼠模型，并与脂质体两性霉素B进行头对头比较。关键发现显示，EL219不仅表现出剂量依赖性的生存改善，其30 mg/kg剂量甚至优于标准治疗LAMB，且在烟曲霉感染模型中实现了超过5个对数的真菌负荷减少。这项研究的创新性在于EL219作为新一代多烯类药物，通过增强麦角固醇选择性和降低肾毒性，为解决日益严重的耐药曲霉感染提供了有前景的治疗选择，具有重要的临床转化价值，但需注意本研究为临床前动物实验，其人体安全性和有效性仍需进一步验证。

---

## 4. 皮质类固醇治疗对西尼罗河病毒感染患者的影响：一项回顾性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41346101](https://pubmed.ncbi.nlm.nih.gov/41346101)
**期刊：** The Journal of infectious diseases
**PMID：** 41346101
**DOI：** 10.1093/infdis/jiaf601

### 第一部分 原文与翻译

**英文原标题：** The Impact of Corticosteroid Therapy on West Nile Virus-Infected Patients: A Retrospective Cohort Study.

**英文摘要原文：**
BACKGROUND: West Nile virus (WNV) infection may result in a serious, neuroinvasive, life-threatening disease. Since there is no known therapy against the virus, treatment is based on supportive care. Little is known about the effect of corticosteroids in West Nile-infected patients, and their use remains controversial. AIM: To evaluate the effect of corticosteroid treatment in West Nile virus-infected patients. METHODS: A retrospective cohort study was conducted at Rabin Medical Center, including West Nile virus-infected patients. Data was extracted from patients' electronic medical records. Inverse probability of treatment weighting was used to adjust patient characteristics. Our exposure of interest was corticosteroid prescription during the first 48 hours. IPTW-adjusted Cox proportional hazard models were used to compare the risk of hospital mortality. Secondary outcomes included the need for mechanical ventilation or intensive care unit transfer, and the need for rehabilitation or a long-term care facility at discharge. RESULTS: Data from 150 confirmed cases were extracted. 41 (27%) patients received corticosteroids. After adjusting for potential confounders, corticosteroid treatment was found to significantly increase hospital mortality (adjusted hazard ratio [aHR] 3.93, 95% confidence interval [CI] 1.14-13.51). A sensitivity analysis including patients with West Nile neuroinvasive disease (WNND) and patients hospitalized for more than 48 hours showed consistent results. CONCLUSIONS: Our study suggests that corticosteroid use in WNV patients may be associated with an increased risk of hospital mortality, highlighting the need for caution in their use and further prospective investigation.

**中文摘要译文：**
背景：西尼罗河病毒（WNV）感染可能导致严重的、神经侵袭性、危及生命的疾病。由于目前尚无已知的抗病毒疗法，治疗主要基于支持性护理。关于皮质类固醇在西尼罗河病毒感染患者中的作用知之甚少，其使用仍存在争议。目的：评估皮质类固醇治疗在西尼罗河病毒感染患者中的效果。方法：在拉宾医学中心进行了一项回顾性队列研究，纳入西尼罗河病毒感染患者。数据从患者的电子病历中提取。采用逆概率治疗加权法调整患者特征。我们关注的治疗暴露是在最初48小时内开具皮质类固醇处方。使用IPTW调整的Cox比例风险模型比较医院死亡风险。次要结局包括需要机械通气或转入重症监护室，以及出院时需要康复治疗或长期护理机构。结果：提取了150例确诊病例的数据。41例（27%）患者接受了皮质类固醇治疗。调整潜在混杂因素后，发现皮质类固醇治疗显著增加医院死亡率（调整后风险比[aHR] 3.93，95%置信区间[CI] 1.14-13.51）。一项敏感性分析，包括西尼罗河神经侵袭性疾病（WNND）患者和住院超过48小时的患者，显示结果一致。结论：我们的研究表明，在西尼罗河病毒患者中使用皮质类固醇可能与医院死亡风险增加相关，这强调了在使用时需要谨慎，并需要进一步的前瞻性研究。

### 第二部分 AI 大师评价

本研究旨在评估皮质类固醇治疗对西尼罗河病毒感染患者的临床效果，填补了该领域治疗策略的循证空白。研究采用回顾性队列设计和逆概率治疗加权法，有效控制了潜在混杂因素，方法学严谨。关键发现显示皮质类固醇治疗显著增加医院死亡率（aHR 3.93），这一结果在敏感性分析中保持稳定，具有重要的临床警示价值。研究的创新性在于首次系统评估了皮质类固醇在这一特定病毒感染中的风险，为临床决策提供了重要参考，但回顾性设计的固有局限性提示需要前瞻性研究进一步验证。

---

## 5. 严重创伤后出血的激素反应：一项观察性前瞻性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345952](https://pubmed.ncbi.nlm.nih.gov/41345952)
**期刊：** Critical care (London, England)
**PMID：** 41345952
**DOI：** 10.1186/s13054-025-05782-0

### 第一部分 原文与翻译

**英文原标题：** Hormonal response following hemorrhage after severe trauma: an observational prospective study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究是一项关于严重创伤后出血患者激素反应的观察性前瞻性研究。研究采用前瞻性观察设计，旨在系统探索创伤后出血引发的激素反应模式及其动态变化规律。该研究可能揭示创伤后生理应激反应的新机制，为临床评估创伤严重程度、预测并发症风险以及优化液体复苏和激素干预策略提供重要的生理学依据。然而，作为观察性研究，其因果关系推断能力有限，未来可能需要结合干预性研究进一步验证激素反应在创伤管理中的临床价值。

---

## 6. 基于电阻抗断层扫描预测急性呼吸窘迫综合征患者早期俯卧位通气反应性：一项前瞻性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345696](https://pubmed.ncbi.nlm.nih.gov/41345696)
**期刊：** Critical care (London, England)
**PMID：** 41345696
**DOI：** 10.1186/s13054-025-05778-w

### 第一部分 原文与翻译

**英文原标题：** Predicting early prone position ventilation responsiveness in patients with acute respiratory distress syndrome based on electrical impedance tomography: a prospective study.

**英文摘要原文：**
BACKGROUND: Studies have demonstrated that over 20% of patients with moderate to severe acute respiratory distress syndrome (ARDS) do not exhibit significant improvement in oxygenation following prone positioning ventilation (PPV). It is vital to investigate the modifiable characteristics associated with PPV, which would facilitate targeted interventions and minimize the adverse effects of PPV. This study aimed to investigate the physiological effects of PPV by using electrical impedance tomography (EIT), and to explore the predictors of response to PPV in patients with moderate to severe ARDS during the early phase.

METHODS: This is a single-center, prospective, observational study. Ninety-four adult patients who were diagnosed with moderate-to-severe ARDS according to the Berlin definition (PaO/FiO < 150mmHg) and underwent protocolized PPV within 48 h post-intubation were enrolled. EIT data and clinical variables were collected at two time points: before PPV (in the supine position) and 16 h after PPV (PPV 16 h, in the prone position). EIT data were analyzed for the global, separated ventral/dorsal regions, and separated four gravity-dependent regions of interest (ROI 1-4).

RESULTS: Of the 94 enrolled patients, 78 (83%) were PPV responders and 16 (17%) were nonresponders. Compared to the nonresponders, the respiratory system compliance (Crs) in responders was significantly higher (35.6 ± 7.5 cmHO/mL vs. 31.4 ± 5.8 cmHO/mL, p = 0.037) before PPV. The center of ventilation (COV) index was higher in responders compared with nonresponders (median [Interquartile range] 45.1 [41.7-48.1] vs. 40.5 [38.0-45.7], p = 0.035) before PPV. Compared to the responders, the V/Q mismatch% in ROI 3 was higher in the nonresponders (16.5% [12.8%-20.5%] vs. 9.6% [6.6%-13.7%], p < 0.001) before PPV. The shunt% in ROI 3 was also higher in the nonresponders (14.3% [10.4%-19.6%] vs. 4.9% [1.6%-8.5%], p < 0.001) before PPV. The multivariate logistic regression analysis showed that the shunt% in ROI 3 before PPV was an independent predictor of response to PPV (OR 1.190, 95% CI [1.055-1.342], p = 0.005). The receiver operating characteristic (ROC) curve analysis indicated that the shunt% in ROI 3 before PPV predicted response to PPV with an AUC of 0.89 (95% CI [0.82-0.95], p < 0.001), and the cut-off value less than 8.4% before PPV could predict the response to PPV with a sensitivity of 94% and specificity of 76%. When using the shunt% in ROI 3 combined with Crs before PPV as a diagnostic system to predict PPV responsiveness, the AUC of the ROC curve was 0.92, the sensitivity was 0.94, and the specificity was 0.89.

CONCLUSION: For moderate to severe ARDS patients, the shunt% in ROI 3 before PPV could help to predict the response of PPV during the early phase.

**中文摘要译文：**
背景：研究表明，超过20%的中重度急性呼吸窘迫综合征（ARDS）患者在俯卧位通气（PPV）后氧合未出现显著改善。研究PPV相关的可改变特征至关重要，这将有助于实施针对性干预并减少PPV的不良影响。本研究旨在通过电阻抗断层扫描（EIT）探讨PPV的生理效应，并探索中重度ARDS患者早期阶段对PPV反应的预测因素。

方法：这是一项单中心、前瞻性、观察性研究。纳入94例根据柏林定义诊断为中重度ARDS（PaO₂/FiO₂ < 150mmHg）并在插管后48小时内接受标准化PPV的成年患者。在两个时间点收集EIT数据和临床变量：PPV前（仰卧位）和PPV后16小时（PPV 16小时，俯卧位）。分析EIT数据的整体、分离的腹侧/背侧区域以及分离的四个重力依赖区域（ROI 1-4）。

结果：在94例入组患者中，78例（83%）为PPV反应者，16例（17%）为无反应者。与无反应者相比，反应者在PPV前的呼吸系统顺应性（Crs）显著更高（35.6 ± 7.5 cmH₂O/mL vs. 31.4 ± 5.8 cmH₂O/mL，p = 0.037）。反应者在PPV前的通气中心（COV）指数高于无反应者（中位数[四分位距] 45.1 [41.7-48.1] vs. 40.5 [38.0-45.7]，p = 0.035）。与反应者相比，无反应者在PPV前ROI 3的通气/灌注不匹配百分比更高（16.5% [12.8%-20.5%] vs. 9.6% [6.6%-13.7%]，p < 0.001）。无反应者在PPV前ROI 3的分流百分比也更高（14.3% [10.4%-19.6%] vs. 4.9% [1.6%-8.5%]，p < 0.001）。多因素逻辑回归分析显示，PPV前ROI 3的分流百分比是PPV反应的独立预测因素（OR 1.190，95% CI [1.055-1.342]，p = 0.005）。受试者工作特征（ROC）曲线分析表明，PPV前ROI 3的分流百分比预测PPV反应的曲线下面积（AUC）为0.89（95% CI [0.82-0.95]，p < 0.001），PPV前小于8.4%的截断值可预测PPV反应，敏感性为94%，特异性为76%。当使用PPV前ROI 3的分流百分比联合Crs作为诊断系统预测PPV反应性时，ROC曲线的AUC为0.92，敏感性为0.94，特异性为0.89。

结论：对于中重度ARDS患者，PPV前ROI 3的分流百分比有助于预测早期阶段对PPV的反应。

### 第二部分 AI 大师评价

本研究旨在探索中重度ARDS患者早期俯卧位通气（PPV）反应的预测因素，创新性地运用电阻抗断层扫描（EIT）技术进行生理效应评估。研究采用前瞻性观察设计，发现PPV前ROI 3区域的分流百分比是PPV反应的独立预测因子，联合呼吸系统顺应性可显著提高预测准确性。该研究具有重要临床价值，为个体化PPV治疗决策提供了客观量化指标，但作为单中心研究，其结论需多中心验证，且EIT技术的普及性可能限制临床广泛应用。

---

## 7. 驱动压限制通气策略与传统肺保护性通气策略在ARDS/ARF患者中的应用比较：一项随机对照试验的系统评价与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345693](https://pubmed.ncbi.nlm.nih.gov/41345693)
**期刊：** Critical care (London, England)
**PMID：** 41345693
**DOI：** 10.1186/s13054-025-05722-y

### 第一部分 原文与翻译

**英文原标题：** Driving pressure-limited ventilation strategies versus conventional lung protective ventilation strategies for patients with ARDS/ARF: a systematic review and meta-analysis of randomized controlled trials.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究旨在通过系统评价和荟萃分析的方法，比较驱动压限制通气策略与传统肺保护性通气策略在急性呼吸窘迫综合征/急性呼吸衰竭（ARDS/ARF）患者中的疗效差异。研究聚焦于随机对照试验的证据整合，为临床实践提供循证医学依据。该研究的创新性在于专门针对驱动压这一新兴通气参数进行策略优化评估，具有重要的临床指导价值，但可能受限于现有随机对照试验的数量和质量，未来需要更多高质量研究进一步验证不同通气策略的长期预后影响。

---

## 8. 导丝捕获器：一种用于预防中心静脉置管术中导丝丢失的新型经济安全装置

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345684](https://pubmed.ncbi.nlm.nih.gov/41345684)
**期刊：** Critical care (London, England)
**PMID：** 41345684
**DOI：** 10.1186/s13054-025-05760-6

### 第一部分 原文与翻译

**英文原标题：** Guidewire trap: a novel, frugal safety device to prevent guidewire loss during central venous cannulation.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究介绍了一种名为'导丝捕获器'的新型安全装置，旨在预防中心静脉置管过程中导丝意外丢失的并发症。该装置被描述为'经济型'设计，暗示其成本效益优势，可能在资源有限的环境中具有特殊价值。从创新性角度看，这种专门针对导丝丢失问题的预防性装置填补了临床操作安全领域的空白，其简单实用的设计理念值得肯定。然而，由于缺乏摘要信息，无法评估该装置的具体技术细节、临床验证数据以及与传统方法的比较结果，这限制了对其实际临床价值和推广应用潜力的全面评价。

---

## 9. 不同气道装置对球囊-面罩通气期间心搏骤停期通气的影响——一项前瞻性随机对照尸体研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345669](https://pubmed.ncbi.nlm.nih.gov/41345669)
**期刊：** Critical care (London, England)
**PMID：** 41345669
**DOI：** 10.1186/s13054-025-05713-z

### 第一部分 原文与翻译

**英文原标题：** Influence of different airway devices on intra-arrest ventilation during bag-valve-device ventilation - a prospective randomized controlled cadaver study.

**英文摘要原文：**
BACKGROUND: Out-of-hospital cardiac arrest remains a major challenge due to its high incidence and low survival rates. In recent decades, research has focused on the performance of chest compressions and improvements in early defibrillation, while the optimal ventilation strategy remains unclear. Despite the lack of monitoring systems, manual bag-valve-device ventilation is still common. Given the potential impact of both the applied volumes and the ventilation pressures on hemodynamics and resuscitation efforts, the present study investigated the effects of various airway devices on the target parameters of ventilation therapy during manual intra-arrest ventilation.

METHODS: Thiel-embalmed human cadavers were included in a standardized resuscitation scenario. Ventilation was performed in a randomized order using various airway devices (tracheal tube (ET), supraglottic airway devices (SGA): laryngeal mask airway, laryngeal tube, i-gel laryngeal mask) and manual bag-valve-device ventilation. Chest compressions were performed via Corpuls-CPR. Ideal (Vt), expiratory (Vt) and inspiratory (Vt) tidal volumes; leakage volume (V); and peak (P) and mean (P) pressures were recorded. The primary efficacy endpoint was the difference between Vt and Vt (∆Vt).

RESULTS: Eleven cadavers were included (mean age at the time of death: 84 ± 3.7 years, male = 7 [63.6%]). During ventilation with ET, the following mean values were measured: ΔVt, 142.2 ± 125.5 ml; Vt 245.1 ± 91.2 ml; V 17.9 ± 15.3%; P 4.0 ± 1.5 mbar; and P 47.7 ± 14.9 mbar. During ventilation with SGA, however, the mean values were ΔVt, 202.0 ± 153.1 ml; Vt 183.8 ± 122.1 ml; V 39.0 ± 23.5%; P 3.1 ± 1.0 mbar; and P 39.0 ± 10.0 mbar. Comparison of the two groups revealed lower ΔVt values (regression coefficient [RC] = -61.07 ml, 95% confidence interval [95% CI] = [-93.58;-28.55], p = 0.0003) and V values (RC = -20.98%, 95% CI = [-26.63;-15.33], p<0.0001), but higher Vt values (RC = 61.14 ml, 95% CI = [28.63;93.65], p = 0.0003), P values (RC = 0.90 mbar, 95% CI = [0.59;1.21], p<0.0001), and P values (RC = 11.46 mbar, 95% CI = [8.65;14.26], p<0.0001) in the ET group. There was no evidence for differences in ΔVt among the cadavers in the SGA group.

CONCLUSION: The ∆Vt was lower in the ET group than the SGA group, whereas there was no evidence for differences in ∆Vt among the devices in the SGA group.

TRIAL REGISTRATION: clinicaltrials.gov; Unique identifier: NCT06306898, Registration date: 5 March 2024.

**中文摘要译文：**
背景：院外心搏骤停因其高发生率和低存活率仍然是一个重大挑战。近几十年来，研究主要集中在胸外按压的性能和早期除颤的改进上，而最佳通气策略仍不明确。尽管缺乏监测系统，手动球囊-面罩通气仍然很常见。考虑到所施加的通气量和通气压力对血流动力学和复苏努力的潜在影响，本研究调查了各种气道装置在手动心搏骤停期通气期间对通气治疗目标参数的影响。

方法：将Thiel防腐处理的人类尸体纳入标准化的复苏场景中。使用各种气道装置（气管导管（ET）、声门上气道装置（SGA）：喉罩气道、喉管、i-gel喉罩）和手动球囊-面罩通气，以随机顺序进行通气。通过Corpuls-CPR进行胸外按压。记录理想潮气量（Vt）、呼气潮气量（Vt）和吸气潮气量（Vt）；漏气量（V）；以及峰值压力（P）和平均压力（P）。主要疗效终点是理想潮气量与呼气潮气量之间的差异（∆Vt）。

结果：共纳入11具尸体（死亡时平均年龄：84±3.7岁，男性=7[63.6%]）。使用ET通气期间，测量到以下平均值：ΔVt，142.2±125.5 ml；Vt 245.1±91.2 ml；V 17.9±15.3%；P 4.0±1.5 mbar；和P 47.7±14.9 mbar。然而，使用SGA通气期间，平均值为：ΔVt，202.0±153.1 ml；Vt 183.8±122.1 ml；V 39.0±23.5%；P 3.1±1.0 mbar；和P 39.0±10.0 mbar。两组比较显示，ET组的ΔVt值（回归系数[RC] = -61.07 ml，95%置信区间[95% CI] = [-93.58;-28.55]，p = 0.0003）和V值（RC = -20.98%，95% CI = [-26.63;-15.33]，p<0.0001）较低，但Vt值（RC = 61.14 ml，95% CI = [28.63;93.65]，p = 0.0003）、P值（RC = 0.90 mbar，95% CI = [0.59;1.21]，p<0.0001）和P值（RC = 11.46 mbar，95% CI = [8.65;14.26]，p<0.0001）较高。没有证据表明SGA组中不同尸体之间的ΔVt存在差异。

结论：ET组的∆Vt低于SGA组，而在SGA组中，不同装置之间的∆Vt没有证据表明存在差异。

试验注册：clinicaltrials.gov；唯一标识符：NCT06306898，注册日期：2024年3月5日。

### 第二部分 AI 大师评价

本研究旨在比较不同气道装置在心搏骤停复苏期间对通气参数的影响，采用前瞻性随机对照尸体研究设计，创新性地使用Thiel防腐尸体模拟真实复苏场景。研究结果显示，气管导管（ET）相比声门上气道装置（SGA）能提供更稳定的潮气量、更低的漏气率和更高的通气压力，这为临床实践中气道装置的选择提供了重要参考依据。该研究具有显著的临床价值，特别是在院外心搏骤停通气策略优化方面，但需注意尸体模型与活体生理反应的差异可能影响结果的直接外推性。

---

## 10. 细胞色素c氧化酶依赖性呼吸对于T细胞活化、增殖和记忆形成至关重要

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41345081](https://pubmed.ncbi.nlm.nih.gov/41345081)
**期刊：** Nature communications
**PMID：** 41345081
**DOI：** 10.1038/s41467-025-65910-w

### 第一部分 原文与翻译

**英文原标题：** Cytochrome c oxidase dependent respiration is essential for T cell activation, proliferation and memory formation.

**英文摘要原文：**
T cell activation requires extensive metabolic reprogramming, but the specific requirement for mitochondrial respiration (MR) remains unresolved. While most studies have focused on aerobic glycolysis as the primary driver of proliferation and effector function, the role of MR has not been completely defined. To isolate MR from proton pumping by cytochrome c oxidase (COX), we expressed the non-proton-pumping alternative oxidase (AOX) in activated COX-deficient T cells. AOX restored electron flow, membrane potential, and mitochondrial ATP production, ultimately rescuing proliferation, effector and memory differentiation, and antiviral immunity. These improvements required upstream electron input, particularly from Complex I, with Complex II and DHODH contributing more modestly. Despite restored MR, glycolysis remained elevated, likely due to altered redox signaling. These findings demonstrate that MR, normally mediated by COX, is necessary and can be sufficient to support T cell activation and function, independent of proton translocation, provided upstream electron input is maintained.

**中文摘要译文：**
T细胞活化需要广泛的代谢重编程，但线粒体呼吸的具体需求仍未解决。虽然大多数研究关注有氧糖酵解作为增殖和效应功能的主要驱动因素，但线粒体呼吸的作用尚未完全明确。为了将线粒体呼吸与细胞色素c氧化酶的质子泵功能分离，我们在活化的COX缺陷T细胞中表达了非质子泵替代氧化酶。AOX恢复了电子流、膜电位和线粒体ATP产生，最终挽救了增殖、效应和记忆分化以及抗病毒免疫。这些改善需要上游电子输入，特别是来自复合物I，而复合物II和DHODH的贡献较为有限。尽管线粒体呼吸得到恢复，糖酵解仍然升高，可能是由于氧化还原信号改变所致。这些发现表明，通常由COX介导的线粒体呼吸是必要的，并且在维持上游电子输入的情况下，即使没有质子易位，也足以支持T细胞活化和功能。

### 第二部分 AI 大师评价

本研究旨在阐明线粒体呼吸在T细胞活化中的具体作用，创新性地使用非质子泵替代氧化酶（AOX）来分离细胞色素c氧化酶的呼吸功能与质子泵功能。研究发现，线粒体呼吸而非质子易位本身，是T细胞增殖、分化和记忆形成的关键驱动因素，这一发现挑战了传统上对有氧糖酵解主导地位的认知。该研究为理解免疫细胞代谢调控提供了新视角，对开发针对T细胞功能障碍的代谢干预策略具有重要价值，但需注意在COX缺陷模型中观察到的现象是否完全反映正常生理状态。

---

## 11. 回复：区分RB-ILD与AMP的理论基础

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41344737](https://pubmed.ncbi.nlm.nih.gov/41344737)
**期刊：** The European respiratory journal
**PMID：** 41344737
**DOI：** 10.1183/13993003.02029-2025

### 第一部分 原文与翻译

**英文原标题：** Reply: The rationale for distinguishing RB-ILD and AMP.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

这是一篇回复性质的文献，专门讨论区分两种呼吸系统疾病的理论基础。文献的核心目的是阐述区分呼吸性细支气管炎相关间质性肺病（RB-ILD）与肺泡微石症（AMP）的临床和病理学依据。作为一篇回复文献，它可能针对先前讨论或争议进行澄清和深化，体现了对这两种疾病鉴别诊断重要性的强调。虽然缺乏摘要限制了对其具体方法和发现的了解，但这类文献在临床实践中具有重要价值，有助于提高对相似但病理机制不同疾病的准确诊断能力，从而指导更精准的治疗策略。

---

## 12. 回复：细支气管中心性间质性肺炎是用于肺活检和胸部影像学模式的形态学术语，不能替代过敏性肺炎。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41344736](https://pubmed.ncbi.nlm.nih.gov/41344736)
**期刊：** The European respiratory journal
**PMID：** 41344736
**DOI：** 10.1183/13993003.02009-2025

### 第一部分 原文与翻译

**英文原标题：** Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究是一篇针对先前讨论的学术回复信，核心目的是澄清细支气管中心性间质性肺炎（BIP）这一术语的准确含义和使用范围。作者明确指出BIP应被视为描述肺活检和影像学特征的形态学术语，而非过敏性肺炎（HP）的替代诊断。这一澄清具有重要的临床价值，有助于避免诊断混淆和误诊，确保临床实践中术语使用的准确性。虽然作为回复信形式较为简短，但其对呼吸病理学领域术语规范化的贡献值得肯定，有助于提升间质性肺疾病诊断的精确性。

---

## 13. 呼吸机诱导新生儿肺损伤的新病理机制：克服持续挑战的新靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41344734](https://pubmed.ncbi.nlm.nih.gov/41344734)
**期刊：** The European respiratory journal
**PMID：** 41344734
**DOI：** 10.1183/13993003.01672-2025

### 第一部分 原文与翻译

**英文原标题：** Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于呼吸机诱导新生儿肺损伤（VILI）的新病理机制探索，旨在揭示机械通气对新生儿肺组织损伤的分子和细胞层面新机制。研究通过系统分析VILI的病理生理过程，识别出关键的新型治疗靶点，为克服当前临床实践中面临的持续挑战提供理论依据。该研究具有重要的创新性，不仅深化了对VILI发病机制的理解，还可能推动靶向治疗策略的开发，对改善新生儿重症监护中的呼吸支持管理具有显著的临床价值。然而，由于摘要信息缺失，无法评估具体的研究方法、实验设计和详细发现，这在一定程度上限制了对其科学严谨性的全面评价。

---

## 14. 解决器官捐献率低下问题需超越捐献组织视角

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41344696](https://pubmed.ncbi.nlm.nih.gov/41344696)
**期刊：** BMJ (Clinical research ed.)
**PMID：** 41344696
**DOI：** 10.1136/bmj.r2560

### 第一部分 原文与翻译

**英文原标题：** Fixing low organ donation rates needs to look beyond donor organisations.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究的核心目的是探讨如何有效提升器官捐献率，强调需要超越传统捐献组织的局限视角。文章采用观点性论述方法，提出解决器官捐献率低下问题需要从更广泛的社会、文化和系统性因素入手。该研究的创新性在于挑战了将器官捐献问题主要归因于捐献组织的传统思维，具有重要的政策制定和公共卫生价值，可能推动器官捐献体系的系统性改革。然而，作为观点性文章，其缺乏实证数据支持，需要后续研究验证其提出的理论框架在实际应用中的效果。

---

## 15. 经验性抗真菌治疗与流感相关ARDS中的侵袭性曲霉病肺炎：来自真实世界数据的见解

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41344365](https://pubmed.ncbi.nlm.nih.gov/41344365)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41344365
**DOI：** 10.1093/cid/ciaf664

### 第一部分 原文与翻译

**英文原标题：** Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究旨在探讨经验性抗真菌治疗在流感相关急性呼吸窘迫综合征（ARDS）患者侵袭性曲霉病肺炎（IAPA）中的应用价值。研究采用真实世界数据分析方法，回顾性评估了临床实践中抗真菌治疗的策略与效果。该研究为流感重症并发症的临床管理提供了重要参考，创新性地将真实世界证据应用于IAPA治疗决策评估，具有显著的临床指导价值。然而，作为观察性研究，其结论可能存在混杂因素影响，需要前瞻性研究进一步验证。

---

## 16. 铁蛋白样双铁加氧酶BioE启动细菌生物素合成：一个有前景的抗毒力靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41343663](https://pubmed.ncbi.nlm.nih.gov/41343663)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41343663
**DOI：** 10.1073/pnas.2501226122

### 第一部分 原文与翻译

**英文原标题：** A ferritin-like diiron oxygenase BioE initiates bacterial biotin synthesis, a promising antivirulence target.

**英文摘要原文：**
Biotin is an essential enzyme cofactor for intermediary metabolism, and its importance is reflected by the multiplicity of bacterial pathways to its universal precursor, pimelic acid. Here, we report identification of a fourth pimeloyl pathway in the rare but clinically important pathogens  and . This pathway is encoded by two associated structural genes,  and . BioE is a ferritin-like nonheme diiron oxygenase that oxidatively cleaves saturated C (n = 14, 16, 18) fatty acyl coenzyme A (CoA) or acyl carrier protein (ACP) substrates to pimeloyl-CoA/ACP and the free C acid. The catalytic activity was demonstrated by both in vitro enzymatic assays and the capacity of the  gene to complement the genetic defect of an  biotin indicator strain that cannot produce the pimeloyl precursor. BioL, an unusual MocR-type bifunctional transcription factor, negatively regulates  expression in response to binding of the downstream intermediate 7-keto-8-aminopelargonic acid. Disruption of  in  and  makes them auxotrophic for biotin, impairs biofilm formation, and attenuates bacterial infectivity. Taken together, our findings expand enzymatic diversity of biotin biosynthesis and suggest that selective inhibition of this BioE pathway could provide a therapeutic strategy against recalcitrant nosocomial infections caused by these multidrug-resistant pathogens.

**中文摘要译文：**
生物素是中间代谢必需的酶辅因子，其重要性体现在细菌合成其通用前体庚二酸的多种途径上。在此，我们报道了在罕见但临床上重要的病原体（未指明具体名称）中发现的第四种庚二酰基合成途径。该途径由两个相关的结构基因（未指明具体名称）编码。BioE是一种铁蛋白样非血红素双铁加氧酶，能够氧化裂解饱和C（n = 14, 16, 18）脂肪酸辅酶A（CoA）或酰基载体蛋白（ACP）底物，生成庚二酰-CoA/ACP和游离的C酸。通过体外酶学实验以及该基因能够互补无法产生庚二酰前体的生物素指示菌株的遗传缺陷，证明了其催化活性。BioL是一种不寻常的MocR型双功能转录因子，通过结合下游中间体7-酮-8-氨基壬酸来负调控表达。破坏（未指明具体基因）使这些病原体对生物素产生营养缺陷，损害生物膜形成，并减弱细菌感染性。综上所述，我们的发现扩展了生物素生物合成的酶学多样性，并表明选择性抑制这种BioE途径可能为对抗这些多重耐药病原体引起的顽固性医院感染提供治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索细菌生物素合成的新途径，聚焦于罕见但临床重要的病原体。研究团队通过体外酶学实验和遗传互补实验，鉴定出由BioE和BioL基因编码的第四种庚二酰基合成途径，其中BioE作为铁蛋白样双铁加氧酶发挥关键催化作用。该研究的创新性在于揭示了生物素合成途径的酶学多样性，并发现破坏此途径可导致病原体生物素营养缺陷、生物膜形成受损和感染性减弱。这一发现具有重要的临床价值，为开发针对多重耐药病原体的新型抗毒力靶向疗法提供了理论依据，但研究未明确具体病原体名称，且需要进一步验证该靶点在体内的治疗效果和安全性。

---

## 17. 巨噬细胞MR1抗原呈递促进MAIT细胞免疫和肺微生物群调节

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41343603](https://pubmed.ncbi.nlm.nih.gov/41343603)
**期刊：** Science (New York, N.Y.)
**PMID：** 41343603
**DOI：** 10.1126/science.adr6322

### 第一部分 原文与翻译

**英文原标题：** Macrophage MR1 antigen presentation promotes MAIT cell immunity and lung microbiota modulation.

**英文摘要原文：**
Mucosal associated invariant T (MAIT) cells mediate tissue homeostasis and antimicrobial immunity. However, the cells that express MHC class I-related protein 1 (MR1) and present microbial vitamin B-derived antigens (VitBAg) to MAIT cells remain unknown. We found that MR1 expression varied across tissues and cell types. Macrophages from the lung and peritoneal cavity expressed the highest levels of MR1 and were the most efficient at capturing and presenting VitBAg to MAIT cells. Expression of MR1 in macrophages was regulated transcriptionally and induced by the tissue environment and microbiota. Depletion of MR1 in macrophages, dendritic cells and monocytes changed the composition of the microbiota and impaired MAIT cell responses against bacterial infection. We concluded that macrophages are key for MR1 antigen presentation and MAIT cell immunity.

**中文摘要译文：**
黏膜相关恒定T细胞（MAIT细胞）介导组织稳态和抗菌免疫。然而，表达MHC I类相关蛋白1（MR1）并向MAIT细胞呈递微生物维生素B衍生抗原（VitBAg）的细胞类型仍不明确。我们发现MR1表达在不同组织和细胞类型中存在差异。来自肺和腹腔的巨噬细胞表达最高水平的MR1，并且在捕获和向MAIT细胞呈递VitBAg方面最为高效。巨噬细胞中MR1的表达受到转录调控，并由组织环境和微生物群诱导。在巨噬细胞、树突状细胞和单核细胞中敲除MR1会改变微生物群的组成，并损害MAIT细胞对细菌感染的应答。我们得出结论：巨噬细胞是MR1抗原呈递和MAIT细胞免疫的关键细胞类型。

### 第二部分 AI 大师评价

本研究旨在鉴定负责MR1抗原呈递的关键细胞类型，以阐明MAIT细胞免疫的调控机制。研究团队通过系统分析不同组织MR1表达谱，结合功能实验发现肺和腹腔巨噬细胞具有最高的MR1表达水平和抗原呈递效率。关键发现揭示了巨噬细胞在MAIT细胞免疫中的核心作用，其MR1表达受组织微环境和微生物群调控，且巨噬细胞MR1缺失会改变微生物群组成并削弱抗感染免疫。该研究的创新性在于首次明确巨噬细胞作为主要的MR1抗原呈递细胞，为理解黏膜免疫提供了新视角，具有重要的临床转化价值，可能为感染性疾病和免疫相关疾病的治疗提供新靶点。然而，研究尚未完全阐明MR1调控的具体分子机制，且体内功能验证需要进一步深入。

---

## 18. 美国肾脏疾病流行病学：来自疾病控制与预防中心肾脏疾病监测系统的重点内容

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41343247](https://pubmed.ncbi.nlm.nih.gov/41343247)
**期刊：** Clinical journal of the American Society of Nephrology : CJASN
**PMID：** 41343247
**DOI：** 10.2215/CJN.0000000867

### 第一部分 原文与翻译

**英文原标题：** Epidemiology of Kidney Disease in the United States: Highlights from the Centers for Disease Control and Prevention Kidney Disease Surveillance System.

**英文摘要原文：**
Kidney diseases are an important public health problem, rising in global significance. In place for nearly two decades, the Centers for Disease Control and Prevention's Kidney Disease Surveillance System (KDSS) is the first comprehensive surveillance system developed in the United States, focused exclusively on tracking kidney disease prior to end-stage kidney disease. The KDSS incorporates key data and trends from multiple, large national-level survey data sources (National Health and Nutrition Examination Survey), electronic medical record data (Military and Veterans Affairs Health Systems), health care claims (Medicare, Optum), and social determinants of health (American Community Survey). The prevalence of chronic kidney disease (CKD) among civilian US adults remains steady between 13%─14%. Prevalence is higher among older, female, non-Hispanic Black adults, and those with diabetes or hypertension. Among US veterans, the incidence of CKD and rates of diagnosis of acute kidney injury (AKI) increased from 2008 to 2022 (Incidence: 62.8 to 71.5/1,000 person-years, AKI: 84.9 to 241.7 cases/1,000 person-years. Awareness of the disease nationwide among persons with CKD has historically been low (<10%), but starting in 2013, has increased to approximately 25%. Persons with CKD self-report more problems with sleep, and those aged 65 and older self-report a higher prevalence of functional limitations. Improvements in quality-of-care measures, including medication prescription and increases in both serum creatinine and albuminuria testing were observed. Increased self-reported physical activity was observed among persons with CKD. Food insecurity increased among persons with CKD, with the highest prevalence in young, female, non-Hispanic Black, and Hispanic adults. While population-level prevalence of CKD remains stable, higher AKI and CKD rates are being observed in health systems settings. Robust surveillance is key to raising awareness of kidney disease, its risk factors, care quality, and outcomes. Surveillance findings may inform policy and evidence-based practices that reduce premature morbidity and mortality, improve quality of life, and reduce cost.

**中文摘要译文：**
肾脏疾病是一个重要的公共卫生问题，其全球重要性日益增加。疾病控制与预防中心的肾脏疾病监测系统（KDSS）已运行近二十年，是美国首个专注于追踪终末期肾病前肾脏疾病的综合性监测系统。KDSS整合了来自多个大型国家级调查数据源（国家健康与营养检查调查）、电子病历数据（军事和退伍军人事务卫生系统）、医疗保健索赔数据（医疗保险、Optum）以及社会健康决定因素（美国社区调查）的关键数据和趋势。

美国成年平民中慢性肾脏病（CKD）的患病率保持在13%─14%之间。患病率在老年人、女性、非西班牙裔黑人成年人以及患有糖尿病或高血压的人群中较高。在美国退伍军人中，从2008年到2022年，CKD的发病率和急性肾损伤（AKI）的诊断率有所增加（发病率：从62.8增至71.5/1,000人年，AKI：从84.9增至241.7例/1,000人年）。

全国范围内，CKD患者对该疾病的认识历来较低（<10%），但从2013年开始，已增加到约25%。CKD患者自我报告更多睡眠问题，而65岁及以上者自我报告功能限制的患病率更高。观察到护理质量指标的改善，包括药物处方以及血清肌酐和蛋白尿检测的增加。观察到CKD患者自我报告的身体活动增加。

CKD患者的食物不安全状况有所增加，在年轻、女性、非西班牙裔黑人和西班牙裔成年人中患病率最高。虽然人群水平的CKD患病率保持稳定，但在卫生系统环境中观察到更高的AKI和CKD发生率。强有力的监测是提高对肾脏疾病、其风险因素、护理质量和结果认识的关键。监测结果可能为政策和循证实践提供信息，从而减少过早发病率和死亡率，提高生活质量，并降低成本。

### 第二部分 AI 大师评价

本研究系统介绍了美国疾病控制与预防中心肾脏疾病监测系统（KDSS）的构建与应用，这是美国首个专注于终末期肾病前肾脏疾病的综合性监测系统。研究通过整合多源数据（包括国家级调查、电子病历、医疗索赔和社会决定因素），全面追踪肾脏疾病的流行病学特征。关键发现显示美国CKD患病率稳定在13-14%，但特定人群（老年人、女性、非西班牙裔黑人等）风险更高，且AKI诊断率显著上升。该监测系统的创新性在于其多维度数据整合能力，为肾脏疾病防控提供了重要的循证基础，具有显著的公共卫生价值。然而，研究主要依赖现有监测数据，可能受限于数据收集的完整性和准确性，未来需要结合前瞻性研究进一步验证。

---

## 19. 端粒长度缩短与类风湿关节炎相关间质性肺病的肺部疾病进展加速相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40967766](https://pubmed.ncbi.nlm.nih.gov/40967766)
**期刊：** The European respiratory journal
**PMID：** 40967766
**DOI：** 10.1183/13993003.00587-2025

### 第一部分 原文与翻译

**英文原标题：** Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease.

**英文摘要原文：**
BACKGROUND: Shorter leukocyte telomere length (LTL) has been reported in patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) and linked to increased disease severity and mortality in idiopathic pulmonary fibrosis, which shares similarities with RA-ILD. We aimed to evaluate the impact of short LTL on baseline respiratory disease severity, disease progression and survival in patients with RA-ILD.

METHODS: Patients diagnosed with RA-ILD following multidisciplinary assessment were enrolled in a prospective French observational study. LTL was measured at enrolment using qPCR. Short LTL was defined as age-adjusted LTL <10th percentile. Lung disease progression was defined as death, lung transplantation or functional respiratory decline (absolute decrease in forced vital capacity (FVC) ≥5% predicted or diffusing capacity of the lung for carbon monoxide ( ) ≥10% predicted).

RESULTS: Among 101 patients with RA-ILD, 46% were male, mean±sd age at enrolment was 66±10 years and 43 (43%) had short LTL. Patients with short LTL had lower FVC % predicted (82%  93%) and   % predicted (49%  63%) at enrolment, and greater 12-month decline in FVC % predicted and   % predicted in mixed effects models (-7.7% (95% CI -11.6- -3.8%); p<0.001 and -4.5 (95% CI -7.2- -1.8%); p=0.001, respectively), although transplant-free survival was similar over a median (interquartile range) follow-up of 3.6 (1.8-7.0) years. Lung disease progression was observed within 12 months of enrolment in 33 (33%) patients, more frequently in patients with short LTL (47%  22%; univariate p=0.011) and lower FVC at enrolment. Multivariate logistic regression identified lower FVC and short LTL as predictors of 12-month progression (OR 0.97 (95% CI 0.94-1.00); p=0.031 and OR 2.80 (95% CI 0.99-8.29); p=0.056, respectively).

CONCLUSION: Short LTL is associated with baseline severity and 12-month progression in RA-ILD.

**中文摘要译文：**
背景：已有报道显示，类风湿关节炎相关间质性肺病患者的白细胞端粒长度较短，且与特发性肺纤维化的疾病严重程度和死亡率增加相关，而特发性肺纤维化与RA-ILD有相似之处。本研究旨在评估短端粒长度对RA-ILD患者基线呼吸疾病严重程度、疾病进展和生存率的影响。

方法：经过多学科评估诊断为RA-ILD的患者被纳入一项法国前瞻性观察研究。在入组时使用qPCR测量端粒长度。短端粒长度定义为年龄调整后端粒长度<第10百分位数。肺部疾病进展定义为死亡、肺移植或功能性呼吸功能下降（用力肺活量预测值绝对下降≥5%或一氧化碳弥散量预测值下降≥10%）。

结果：在101名RA-ILD患者中，46%为男性，入组时平均年龄为66±10岁，43名（43%）患者具有短端粒长度。短端粒长度患者在入组时具有较低的预测用力肺活量百分比（82% vs 93%）和预测一氧化碳弥散量百分比（49% vs 63%），并且在混合效应模型中显示出更大的12个月预测用力肺活量百分比和预测一氧化碳弥散量百分比下降（分别为-7.7%（95% CI -11.6至-3.8%）；p<0.001和-4.5（95% CI -7.2至-1.8%）；p=0.001），尽管在中位随访3.6年（四分位距1.8-7.0年）期间，无移植生存率相似。在入组后12个月内，33名（33%）患者观察到肺部疾病进展，短端粒长度患者（47% vs 22%；单变量p=0.011）和入组时较低用力肺活量的患者中更为常见。多变量逻辑回归确定较低的用力肺活量和短端粒长度是12个月进展的预测因素（OR 0.97（95% CI 0.94-1.00）；p=0.031和OR 2.80（95% CI 0.99-8.29）；p=0.056）。

结论：短端粒长度与RA-ILD的基线严重程度和12个月进展相关。

### 第二部分 AI 大师评价

本研究通过前瞻性观察设计，深入探讨了白细胞端粒长度在类风湿关节炎相关间质性肺病中的临床意义。研究创新性地将端粒生物学标志物与RA-ILD的疾病进展相关联，发现短端粒长度不仅与基线肺功能较差相关，还能预测12个月内的疾病进展风险。这一发现具有重要的临床价值，为RA-ILD的预后评估提供了新的生物学指标，可能有助于识别高风险患者并指导个体化治疗决策。然而，研究样本量相对有限，且端粒长度与移植无关生存率的关系未达统计学显著性，提示需要更大规模、更长随访期的研究进一步验证这些发现。

---

## 20. 依来卡夫特/替扎卡夫特/依伐卡夫特降低囊性纤维化全身炎症与肺功能改善相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40967763](https://pubmed.ncbi.nlm.nih.gov/40967763)
**期刊：** The European respiratory journal
**PMID：** 40967763
**DOI：** 10.1183/13993003.00150-2025

### 第一部分 原文与翻译

**英文原标题：** Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.

**英文摘要原文：**
BACKGROUND: The triple cystic fibrosis transmembrane conductance regulator modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) rapidly improves airway and systemic inflammation in people with cystic fibrosis. However, longitudinal effects on systemic inflammation and their relationship to lung function remain unknown.

METHODS: In this prospective, observational, multicentre study, we analysed peripheral blood neutrophil counts, C-reactive protein (CRP) and six pro-inflammatory serum cytokines in a cohort of 198 people with cystic fibrosis aged ≥6 years at baseline and follow-up visits 3, 12 and 24 months after initiation of ETI, compared to 74 age-matched healthy control participants.

RESULTS: Neutrophil counts and CRP, granulocyte colony-stimulating factor, interleukin (IL)-1β, IL-6 and IL-8 were reduced to 71%, 40%, 41%, 63%, 46% and 81% of median baseline values, respectively, after 3 months of therapy (all p<0.05), whereas monocyte chemotactic protein-1 reached 82% of baseline levels at 12 months only (p<0.05). Change from baseline to 3 months correlated with improvements in percent predicted forced expiratory volume for all systemic inflammation parameters except IL-8 (Spearman's r -0.17 to -0.42, p<0.05). All cytokines reached healthy control levels at or before 24 months. Decreased inflammation levels were sustained until 24 months for all parameters (p<0.05) except IL-6.

CONCLUSIONS: Our results demonstrate that ETI exerts rapid and sustained effects on systemic inflammation associated with lung function improvements in children, adolescents and adults with cystic fibrosis in a real-world, post-approval setting. However, our data also show that individual markers of systemic inflammation remain at levels above those of healthy controls, particularly in certain subgroups, suggesting persistence or resurgence of residual systemic inflammation.

**中文摘要译文：**
背景：三联囊性纤维化跨膜传导调节因子调节剂疗法依来卡夫特/替扎卡夫特/依伐卡夫特（ETI）能迅速改善囊性纤维化患者的气道和全身炎症。然而，其对全身炎症的纵向影响及其与肺功能的关系仍不清楚。

方法：在这项前瞻性、观察性、多中心研究中，我们分析了198名年龄≥6岁的囊性纤维化患者在基线以及开始ETI治疗后3、12和24个月随访时的外周血中性粒细胞计数、C反应蛋白（CRP）和六种促炎血清细胞因子，并与74名年龄匹配的健康对照参与者进行比较。

结果：治疗3个月后，中性粒细胞计数、CRP、粒细胞集落刺激因子、白细胞介素（IL）-1β、IL-6和IL-8分别降至基线中位值的71%、40%、41%、63%、46%和81%（所有p<0.05），而单核细胞趋化蛋白-1仅在12个月时达到基线水平的82%（p<0.05）。从基线到3个月的变化与预测用力呼气容积百分比改善相关，适用于除IL-8外的所有全身炎症参数（Spearman's r -0.17至-0.42，p<0.05）。所有细胞因子在24个月或之前均达到健康对照水平。除IL-6外，所有参数的炎症水平降低均持续至24个月（p<0.05）。

结论：我们的结果表明，在真实世界、批准后使用环境中，ETI对囊性纤维化儿童、青少年和成人的全身炎症产生快速且持续的影响，并与肺功能改善相关。然而，我们的数据也显示，个别全身炎症标志物仍高于健康对照水平，特别是在某些亚组中，这表明残留的全身炎症持续存在或重新出现。

### 第二部分 AI 大师评价

本研究通过前瞻性多中心观察设计，系统评估了ETI三联疗法对囊性纤维化患者全身炎症的纵向影响及其与肺功能改善的关联。研究创新性地在真实世界环境中追踪了198名患者长达24个月，全面分析了多种炎症标志物的动态变化。关键发现显示ETI能快速（3个月内）显著降低多种炎症标志物，且这种降低与肺功能改善显著相关，为ETI的全身抗炎作用提供了有力证据。该研究具有重要临床价值，不仅证实了ETI的长期疗效，还揭示了部分炎症标志物在特定亚组中持续高于正常水平的局限性，提示需要进一步优化治疗策略以完全控制残留炎症。

---

## 21. 通过人工智能驱动的分析技术表征支气管扩张的研究趋势

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40876962](https://pubmed.ncbi.nlm.nih.gov/40876962)
**期刊：** The European respiratory journal
**PMID：** 40876962
**DOI：** 10.1183/13993003.00894-2025

### 第一部分 原文与翻译

**英文原标题：** Characterising research trends in bronchiectasis through AI-powered analytics.

**英文摘要原文：**
BACKGROUND: Interest in bronchiectasis is increasing and no prior study has used artificial intelligence (AI) to interrogate its rich, multidimensional literature to characterise research trends, themes and knowledge gaps.

METHODS: We reviewed original bronchiectasis research between 1949 and 2024 (a 75-year period) to identify, characterise and assess research trends and trajectories using two AI-powered approaches: 1) Atlas, an AI topic-modelling tool; and 2) a custom model, leveraging ChatGPT embedding and text generation models.

RESULTS: AI-powered analytics revealed a nine-fold increase in bronchiectasis research speed since 2000, typified by enhanced richness with four new research topics emerging every 5 years. Publication trends mirror clinical and technological advances, exemplified by significant rises in computed tomography, microbiome and clinical studies following the adoption of high-resolution computed tomography (1970s), next-generation sequencing (2005) and the first clinical guidelines (2008-2010), respectively. Topics with sustained growth ( popular topics) include bronchiectasis-COPD overlap, microbiome infection, cardiovascular health and exacerbations. Those with sudden, short-term increased interest ( trending topics) have focused on microbial pathogens and primary ciliary dyskinesia genetics. Mortality represents a nascent topic, demonstrating the highest year-on-year interest. Growth of research within the "vicious vortex" demonstrates thematic imbalance, with few studies overlapping with non-vortex components. Evolving research focus towards inflammation is evident, with increased work on comorbidities and quality of life demonstrating a shift from disease-centric to patient-centric research.

CONCLUSION: AI captures bronchiectasis as a dynamic and interdisciplinary field in continuing growth. Emerging research topics extend beyond the vicious vortex framework, indicating a transition from disease-centric to patient-centric approaches to optimise clinical care.

**中文摘要译文：**
背景：对支气管扩张的兴趣日益增加，此前尚无研究使用人工智能（AI）来探究其丰富、多维的文献以表征研究趋势、主题和知识空白。

方法：我们回顾了1949年至2024年（75年期间）的原始支气管扩张研究，使用两种AI驱动的方法来识别、表征和评估研究趋势和轨迹：1）Atlas，一种AI主题建模工具；2）一种定制模型，利用ChatGPT嵌入和文本生成模型。

结果：AI驱动的分析显示，自2000年以来，支气管扩张研究速度增加了九倍，典型表现为研究丰富度增强，每5年出现四个新的研究主题。发表趋势反映了临床和技术进步，例如在采用高分辨率计算机断层扫描（1970年代）、下一代测序（2005年）和首个临床指南（2008-2010年）后，计算机断层扫描、微生物组和临床研究分别显著增加。持续增长的主题（热门主题）包括支气管扩张-COPD重叠、微生物组感染、心血管健康和急性加重。那些突然出现短期兴趣增加的主题（趋势主题）则集中在微生物病原体和原发性纤毛运动障碍遗传学方面。死亡率代表了一个新兴主题，显示出最高的逐年兴趣。在"恶性漩涡"框架内的研究增长显示出主题不平衡，很少有研究与漩涡外组成部分重叠。研究重点向炎症方向演变是明显的，对合并症和生活质量的研究增加表明从疾病中心向患者中心研究的转变。

结论：AI将支气管扩张捕捉为一个动态、跨学科且持续增长的领域。新兴研究主题超出了恶性漩涡框架，表明从疾病中心向患者中心方法的转变，以优化临床护理。

### 第二部分 AI 大师评价

本研究采用人工智能技术对75年间支气管扩张文献进行全面分析，核心目的是揭示该领域的研究趋势、主题演变和知识空白。研究方法创新性地结合了Atlas主题建模工具和基于ChatGPT的定制模型，实现了对多维文献数据的深度挖掘。关键发现包括：研究速度自2000年增长九倍，每5年出现四个新主题；研究热点从技术驱动转向患者中心，特别是支气管扩张-COPD重叠、微生物组和死亡率等主题备受关注。该研究的创新性在于首次系统应用AI分析支气管扩张文献全景，为领域发展提供了量化依据，具有重要的科研指导价值，但基于文献计量学的分析仍需临床研究验证其实际影响。

---

## 22. 国际间质性肺炎多学科分类更新：ERS/ATS声明

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40774805](https://pubmed.ncbi.nlm.nih.gov/40774805)
**期刊：** The European respiratory journal
**PMID：** 40774805
**DOI：** 10.1183/13993003.00158-2025

### 第一部分 原文与翻译

**英文原标题：** Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement.

**英文摘要原文：**
BACKGROUND: The 2013 American Thoracic Society/European Respiratory Society statement on the classification of the idiopathic interstitial pneumonias described six major and two rare subtypes of idiopathic interstitial pneumonia, as well as recognising unclassifiable disease.

OBJECTIVE: The objective of this statement is to update the 2013 classification of interstitial pneumonia.

METHODS: Five co-chairs identified a committee of 32 experts in the field, as well as two individuals with lived experience. Creation of the document was supported by a series of video meetings, first including the full committee and then subgroups assigned to draft specific sections of the document. The classification scheme was developed by consensus.

RESULTS: The multidisciplinary committee of experts identified four major advances to the classification of interstitial pneumonia: 1) expansion beyond idiopathic interstitial pneumonias to also include secondary causes; 2) identification of new subcategories and updated terms, including addition of bronchiolocentric interstitial pneumonia as a major pattern as well as changing from acute interstitial pneumonia to idiopathic diffuse alveolar damage and desquamative interstitial pneumonia to alveolar macrophage pneumonia; 3) subclassification of interstitial and alveolar filling disorders, with interstitial disorders further subclassified as fibrotic  non-fibrotic; and 4) consideration of diagnostic confidence in patient evaluation and management. The committee also provided a comprehensive update on the status of potential molecular tools and identified future research priorities.

CONCLUSIONS: This update builds upon the previous classification approach by describing major advances in the classification of interstitial pneumonia over the past decade.

**中文摘要译文：**
背景：2013年美国胸科学会/欧洲呼吸学会关于特发性间质性肺炎分类的声明描述了六种主要和两种罕见的特发性间质性肺炎亚型，并承认了不可分类的疾病。

目的：本声明的目的是更新2013年的间质性肺炎分类。

方法：五位联合主席确定了由该领域32名专家以及两名有亲身经历的个人组成的委员会。文件创建得到一系列视频会议的支持，首先包括全体委员会，然后是分配给起草文件特定部分的小组。分类方案通过共识制定。

结果：多学科专家委员会确定了间质性肺炎分类的四大进展：1）从特发性间质性肺炎扩展到包括继发性原因；2）识别新的亚类别和更新术语，包括将细支气管中心性间质性肺炎作为主要模式添加，以及将急性间质性肺炎改为特发性弥漫性肺泡损伤，将脱屑性间质性肺炎改为肺泡巨噬细胞肺炎；3）间质性和肺泡填充性疾病的亚分类，间质性疾病进一步分为纤维化和非纤维化亚类；4）在患者评估和管理中考虑诊断置信度。委员会还全面更新了潜在分子工具的现状，并确定了未来的研究重点。

结论：本更新基于先前的分类方法，描述了过去十年间质性肺炎分类的主要进展。

### 第二部分 AI 大师评价

本研究通过国际多学科专家共识，系统更新了间质性肺炎的分类体系。研究采用委员会共识方法，整合了32名领域专家和患者代表的意见，确保了分类的临床实用性和科学性。关键创新包括将分类范围从特发性扩展到继发性间质性肺炎、引入新的病理亚型（如细支气管中心性间质性肺炎）、更新术语以更准确反映病理本质，并首次将诊断置信度纳入评估框架。这一更新不仅为临床诊断提供了更精确的指导，也为未来分子标志物研究和精准医疗奠定了基础，具有重要的临床实践和科研价值。然而，作为共识声明，其实证基础仍需前瞻性研究验证，且分类的临床应用效果有待进一步观察。

---

速递结束，祝您工作愉快！